Acute Angle-Closure Glaucoma Associated with Topiramate
Immediate Management
- The American Academy of Ophthalmology recommends discontinuing topiramate urgently as this medication causes acute myopia and secondary angle-closure glaucoma through ciliary body swelling and anterior displacement of the lens-iris diaphragm 1, 2
- Refer patients emergently to ophthalmology for intraocular pressure management, which may include topical medications, systemic agents, or surgical intervention 2
- Do not perform laser peripheral iridotomy as the mechanism differs from primary angle-closure glaucoma—topiramate causes anterior rotation of the ciliary body rather than pupillary block 2
Clinical Context
- Topiramate-induced acute angle-closure glaucoma typically presents bilaterally, unlike primary angle-closure which is often unilateral initially 1
- This condition usually occurs within the first 2 weeks to 1 month of starting therapy 1
- The condition resolves with drug discontinuation, though acute management of elevated intraocular pressure is still required 2
- This is an absolute contraindication to future topiramate use 2
Alternative Therapy Considerations
- For patients with idiopathic intracranial hypertension (IIH), switch to acetazolamide as the first-line carbonic anhydrase inhibitor, with dose escalation as tolerated 3
- Acetazolamide does not carry the same risk of acute angle-closure glaucoma 3
- Consider alternative migraine preventive medications that do not carry this ocular risk for patients using topiramate for migraine prophylaxis 3
- Weight management and lifestyle modifications remain important for IIH patients 3